Goldman Sachs Group Inc. Grows Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Goldman Sachs Group Inc. boosted its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 28.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,118,849 shares of the company’s stock after buying an additional 472,654 shares during the quarter. Goldman Sachs Group Inc. owned approximately 2.42% of Day One Biopharmaceuticals worth $30,935,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Quintet Private Bank Europe S.A. raised its holdings in Day One Biopharmaceuticals by 43.2% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after purchasing an additional 1,000 shares in the last quarter. Parkman Healthcare Partners LLC lifted its position in Day One Biopharmaceuticals by 34.2% in the fourth quarter. Parkman Healthcare Partners LLC now owns 625,749 shares of the company’s stock valued at $9,136,000 after acquiring an additional 159,341 shares during the last quarter. Braidwell LP boosted its stake in Day One Biopharmaceuticals by 13.5% in the fourth quarter. Braidwell LP now owns 4,215,573 shares of the company’s stock valued at $61,547,000 after acquiring an additional 500,000 shares in the last quarter. Superstring Capital Management LP purchased a new position in shares of Day One Biopharmaceuticals during the fourth quarter worth about $5,543,000. Finally, NEOS Investment Management LLC acquired a new stake in shares of Day One Biopharmaceuticals during the fourth quarter worth about $226,000. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

DAWN has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday. The Goldman Sachs Group cut their target price on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a report on Tuesday, February 27th. Piper Sandler reiterated an “overweight” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 26th. JPMorgan Chase & Co. lifted their price objective on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a research note on Monday, April 22nd. Finally, Wedbush reiterated an “outperform” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Tuesday, May 7th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $37.67.

Day One Biopharmaceuticals Trading Up 4.3 %

Shares of DAWN opened at $13.68 on Friday. The stock’s 50 day moving average is $14.68 and its two-hundred day moving average is $14.70. Day One Biopharmaceuticals, Inc. has a twelve month low of $9.67 and a twelve month high of $18.07. The firm has a market capitalization of $1.20 billion, a PE ratio of -5.45 and a beta of -1.53.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings results on Monday, May 6th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.05). On average, sell-side analysts predict that Day One Biopharmaceuticals, Inc. will post -2.69 EPS for the current year.

Insiders Place Their Bets

In related news, insider Samuel C. Blackman sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $16.01, for a total value of $160,100.00. Following the completion of the sale, the insider now owns 1,184,662 shares in the company, valued at $18,966,438.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 10,000 shares of the stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $16.01, for a total value of $160,100.00. Following the completion of the transaction, the insider now directly owns 1,184,662 shares of the company’s stock, valued at $18,966,438.62. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Jeremy Bender sold 70,051 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $17.88, for a total value of $1,252,511.88. Following the sale, the chief executive officer now directly owns 651,762 shares in the company, valued at approximately $11,653,504.56. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 185,534 shares of company stock worth $3,236,030. Corporate insiders own 8.40% of the company’s stock.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.